IPO
Suven Life Sciences Limited announced its Un-audited financial results for the quarter ended 31st December 2018.
Cash position of €207.2 million as of December 31, 2018, compared to €273.8 million as of December 31, 2017
Immunicum AB announced that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in February.
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
The subscription price for warrant TO1 in Promore Pharma AB has been determined according to the terms and conditions forthe warrants to 23.30 SEK per share.
Immunicum AB has, as previously announced, implemented a share issue with preferential rights for the Company’s existing shareholders.
Immunicum AB announced the composition of the Nomination Committee on 19 October 2018.
Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.
Numerous biotech companies had filed for initial public offerings (IPOs) during the five-week government shutdown, but were unlikely to actually be able to be listed until the U.S. Securities and Exchange Commission (SEC) had a chance to review their filings.
TESARO, Inc. announced that pursuant to the terms of the Indenture and the First Supplemental Indenture to the Indenture governing the terms of its 3.00% Convertible Senior Notes due 2021
PRESS RELEASES